| Title |
Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, February 2014
|
| DOI | 10.2147/ndt.s57909 |
| Pubmed ID | |
| Authors |
Klaus Hager, Alan S Baseman, Jeffrey S Nye, H Robert Brashear, John Han, Mary Sano, Bonnie Davis, Henry M Richards |
| Abstract |
Currently available treatments for Alzheimer's disease (AD) can produce mild improvements in cognitive function, behavior, and activities of daily living in patients, but their influence on long-term survival is not well established. This study was designed to assess patient survival and drug efficacy following a 2-year galantamine treatment in patients with mild to moderately severe AD. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 148 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 1% |
| Japan | 2 | 1% |
| Spain | 2 | 1% |
| Brazil | 1 | <1% |
| Portugal | 1 | <1% |
| Unknown | 140 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 25 | 17% |
| Researcher | 23 | 16% |
| Student > Ph. D. Student | 18 | 12% |
| Student > Master | 17 | 11% |
| Student > Postgraduate | 8 | 5% |
| Other | 22 | 15% |
| Unknown | 35 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 25% |
| Psychology | 20 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 7% |
| Agricultural and Biological Sciences | 8 | 5% |
| Biochemistry, Genetics and Molecular Biology | 7 | 5% |
| Other | 19 | 13% |
| Unknown | 46 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2022.
All research outputs
#3,342,999
of 25,374,647 outputs
Outputs from Neuropsychiatric Disease and Treatment
#466
of 3,132 outputs
Outputs of similar age
#38,196
of 322,718 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#4
of 58 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,718 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.